United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

According to Reuters, Pfizer Inc ((NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) have reportedly withdrawn their application for the emergency-use nod of its COVID-19 vaccine in India, as the Company failed to meet drug regulator's (Central Drugs Standard Control Organization) demand for small local trial on the vaccine's safety and immunogenicity for Indians. Unlike other companies conducting small studies in India for foreign-developed vaccines, Pfizer had sought an exception citing approvals it had received elsewhere based on trials in countries such as the U.S. and Germany.

Pfizer Drops India Vaccine Application After Regulator Seeks Local Trial - Reuters

People who were previously infected with coronavirus were more likely to report having full-body reactions.

More Than One In Three People In U.K. Study Report Side Effects From Pfizer Coronavirus Vaccine

Chevron

Dow Inc

Realty Income Corp

Verizon

The song remains the same, and it will for the foreseeable future. The Federal Reserve probably will not be raising rates until 2023, so we remain in a setting with coupons on government securities still close to generational lows.

5 Very Safe High-Dividend Stocks to Buy Now for Worried Investors

AstraZeneca

According to Reuters, the United Kingdom has launched a pioneering clinical study to test whether alternating the AstraZeneca Plc (NASDAQ: AZN), and Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines in a two-shot schedule is safe and effective in fighting the infection.

UK To Test Combining Pfizer And AstraZeneca Vaccines In Two-Shot Regimen

Around $15 billion from coronavirus vaccine sales this year will be just the beginning.

Here's Why Pfizer's a Great Stock to Buy and Hold Now

Moderna

Novavax

Should Investors Worry About New Coronavirus Variants?

This week is all about healthcare with Pfizer Inc. (NYSE: PFE), Sanofi SA (NASDAQ: SNY), Regeneron Pharmaceticals Inc (NASDAQ: REGN), and Bristol-Myers Squibb Co (NYSE: BMY) reporting earnings. But, what is under the spotlight is the effort pharmaceutical and biotech companies are making to combat COVID-19 or more precisely, the vaccine.

Pfizer Is Ready, Even For COVID-19 Variants

The staggering stat was revealed Tuesday in a financial forecast from the Manhattan-based drugmaker, which said its revenue for the year would range between $59 billion and $61 billion.

Pfizer expects $15 billion in COVID-19 vaccine sales in 2021

Leading pharmaceutical research development company Pfizer Inc. (NYSE:PFE) has released solid revenue for the fourth quarter alongside some lofty expectations for 2021.

Pfizer Posts Strong Revenue and Big Expectations for 2021

Investors weren't impressed with the results, despite double-digit percentage increases on both the top and bottom lines.

Coronavirus Vaccine Maker Pfizer Posts a Mixed Q4

Pfizer, Inc. (PFE) CEO Dr. Albert Bourla on Q4 2020 Results - Earnings Call Transcript

Pfizer CEO Albert Bourla says he has grown more confident about the outlook for the vaccine.

Pfizer Increased Vaccine Sales Estimate After AstraZeneca and J&J Stumbles

The shares of Pfizer Inc (NYSE:PFE) are down 3.1% at $34.69 at last check, after the drugmaker reported  an earnings miss alongside better-than-expected revenue.

Options Bulls Blast Pfizer Stock After Earnings

Pfizer stock took a hit in early February on a disappointing fourth-quarter report, though the company called for $15 billion in full-year Covid vaccine sales. So, is Pfizer stock a buy now?

Is Pfizer Stock A Buy On Guidance For $15 Billion In Covid Vaccine Sales?

Pfizer's chief executive officer is confident that the company can deliver 2 billion doses of the company's COVID-19 vaccine to the world in 2021 and 200 million doses to the US by the end of May.  "We forsee no issues with delivering the commitments we have made," CEO Albert Bourla said on the company's fourth-quarter earnings conference call Tuesday. He touted Pfizer's manufacturing and distribution so far of its two-dose COVID-19 vaccine, which was developed with BioNTech and emergency approved by the FDA in December. A two-dose vaccine from Moderna was emergency approved shortly after.

Pfizer's CEO says he sees 'no issues' in delivering 2 billion COVID-19 vaccines on time (PFE)

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

AMC Entertainment

Amazon

GameStop

Alphabet

SPDR S&P 500 ETF Trust

We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.

Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS

Pfizer Inc. (NYSE: PFE), the first company to obtain emergency use authorization for a coronavirus vaccine, offered a preview Tuesday into the vaccine's revenue potential in the current fiscal year. Pfizer's COVID-19 vaccine was co-developed with German partner BioNTech SE – ADR (NASDAQ: BNTX).

Pfizer Expects COVID-19 Vaccine To Bring $15B In Revenue This Year

It's why the market shrugged off the big drugmaker's fourth-quarter earnings miss.

Why Pfizer's Q4 Results Simply Don't Matter Very Much

Pfizer expects to earn approximately $15 billion in revenue from its Covid-19 vaccine this year, the company said Tuesday.

Pfizer expects to rake in sales of $15 billion from its Covid-19 vaccine this year

Pfizer is planning to deliver 200 million doses of its coronavirus vaccine to the U.S. by May, earlier than its initial forecast of July.

Pfizer plans to deliver 200 million doses of Covid vaccine to U.S. by May, sooner than expected

Pfizer Inc. (NYSE: PFE) said on Tuesday that its profit in the fiscal fourth quarter came in weaker than expected. Revenue, on the other hand, topped analysts' estimates in Q4.

Pfizer's profit comes in weaker than expected in the fourth quarter

Pfizer (PFE) delivered earnings and revenue surprises of -8.70% and 6.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Misses Q4 Earnings Estimates

Pfizer stock edged higher on Tuesday after the pharmaceutical company reported adjusted earnings of 42 cents per share on $11.68 billion in sales for its fourth quarter ended Dec. 31. The post Pfizer Stock Inches Up Despite Light Fourth-Quarter Earnings appeared first on Investor's Business Daily.

Pfizer Stock Inches Up Despite Light Fourth-Quarter Earnings

Shares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drugmaker said the COVID-19 vaccine it developed with BioNTech SE is expected to generate about $15 billion in sales in 2021. BioNTech's shares gained 0.6% in the premarket on Tuesday.

News for Pfizer Stock (PFE)